All‐cause mortality at 1 year · people with advanced biliary tract carcinomas
It is very uncertain whether gemcitabine plus oxaliplatin changes all‐cause mortality at 1 year compared with 5‐fluorouracil plus cisplatin plus radiotherapy (very low certainty).
1 finding from 1 review
Serious adverse events · people with advanced biliary tract carcinomas
It is very uncertain whether gemcitabine plus oxaliplatin changes serious adverse events compared with 5‐fluorouracil plus cisplatin plus radiotherapy (very low certainty).
1 finding from 1 review
Health‐related quality of life · people with advanced biliary tract carcinomas
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall response rate · people with advanced biliary tract carcinomas
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to progression of the tumour · people with advanced biliary tract carcinomas
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall response rate · people with advanced biliary tract carcinomas
It is very uncertain whether gemcitabine plus vandetanib changes overall response rate compared with vandetanib (very low certainty).
1 finding from 1 review
All‐cause mortality at 1 year · people with advanced biliary tract carcinomas
It is very uncertain whether gemcitabine plus mitomycin C changes all‐cause mortality at 1 year compared with capecitabine plus mitomycin C (very low certainty).
1 finding from 1 review
Serious adverse events · people with advanced biliary tract carcinomas
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · people with advanced biliary tract carcinomas
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall response rate · people with advanced biliary tract carcinomas
It is very uncertain whether gemcitabine plus mitomycin C changes overall response rate compared with capecitabine plus mitomycin C (very low certainty).
1 finding from 1 review
Time to progression of the tumour · people with advanced biliary tract carcinomas
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Grade 1 ‐ 4 thrombocytopenia · people with advanced biliary tract carcinomas
It is very uncertain whether gemcitabine plus mitomycin C changes grade 1 ‐ 4 thrombocytopenia compared with capecitabine plus mitomycin C (very low certainty).
1 finding from 1 review
Time to progression of the tumour · people with advanced biliary tract carcinomas
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Grade 1 ‐ 4 anaemia · people with advanced biliary tract carcinomas
It is very uncertain whether gemcitabine plus vandetanib changes grade 1 ‐ 4 anaemia compared with vandetanib (very low certainty).
1 finding from 1 review
All‐cause mortality at 1 year · people with advanced biliary tract carcinomas
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with advanced biliary tract carcinomas
It is very uncertain whether gemcitabine changes serious adverse events compared with vandetanib (very low certainty).
1 finding from 1 review
Helath‐related quality of life · people with advanced biliary tract carcinomas
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Severe visual impairment or blindness at 6 to 12 months' corrected age · Prevention of retinopathy of prematurity in preterm infants
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Rescue treatment with anti‐VEGF agents · Prevention of retinopathy of prematurity in preterm infants
Systemic administration of beta‐blockers may leads to lower rescue treatment with anti‐VEGF agents compared with placebo or no treatment (low certainty).
1 finding from 1 review
Treatment with laser photocoagulation or cryotherapy · Prevention of retinopathy of prematurity in preterm infants
Systemic administration of beta‐blockers may leads to lower treatment with laser photocoagulation or cryotherapy compared with placebo or no treatment (low certainty).
1 finding from 1 review